Call for Abstract
9th Annual Congress on Drug Design & Drug Formulation , will be organized around the theme ““Advanced Drug Design and Formulation Techniques to enhance Therapeutic Outcome” ”
Drug Formulation 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Drug Formulation 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Rational Drug design or drug design is the method of inventing innovative medications. Drug design defines the design of molecules that are corresponding in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which repeatedly results in a medicinal benefit to the patient. Discovery of effective drugs is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether conversations occur. Basically, drug design involves design of small molecules that are harmonizing in shape and charge to the bio molecular target to which they act together and consequently will bind to it.
The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to expect the conformation of the small molecule and to model conformational deviations in the biological target that may occur when the small molecule binds to it.
- Track 1-1Toxicology measures in therapeutic proteins
- Track 1-2Receptor-based Drug Design
- Track 1-3Molecular graphics
- Track 1-4Antimetabolites
- Track 1-5Pharmacophore-based Drug Design
- Track 1-6Structural based drug designing
- Track 1-7Drug Designing Docking
By using computational methods and the 3D structural information of the protein target, we are now able to scrutinise the detailed underlying molecular and atomic interactions involved in ligand:protein interactions and thus interpret experimental results in detail. The use of computers in drug discovery bears the additional advantage of delivering new drug candidates more rapidly and cost-efficiently. Computer-aided drug discovery has recently had important successes: new ligands have been predicted along with their receptor-bound structures and in several circumstances the achieved hit rates (ligands discovered per molecules tested) have been significantly greater than through experimental high-throughput screening. Strategies for CADD vary depending on the extent of structural and other information available regarding the target (enzyme/receptor) and the ligands. Computer-aided drug design (CADD) is an exciting and diverse discipline where various aspects of applied and basic research merge and stimulate each other. In the early stage of a drug discovery process, researchers may be faced with little or no structure activity relationship (SAR) information. The process by which a new drug is brought to market stage is mentioned to by a number of names most commonly as the development chain or “pipeline” and comprises of a number of distinct stages. To design a rational drug, we must firstly find out which proteins can be the drug targets in pathogenesis. In present review we reported a brief history of CADD, DNA as target, receptor theory, structure optimization, structure-based drug design, virtual high-throughput screening (vHTS), graph machines. All the world’s major pharmaceutical and biotechnology companies use computational design tools.
- Track 2-1Steps Involved in CADD
- Track 2-2x-ray crystallography & NMR spectroscopy
- Track 2-3Bioinformatics in CADD
- Track 2-4Ligand based CADD
- Track 2-5Homology modelling
- Track 2-6Biomarkers in medical science
- Track 2-7In silico molecular design software and tools
Molecular modeling has become a valuable and essential tool to medicinal chemists in the drug design process. Molecular modeling designates the generation, manipulation or representation of three-dimensional structures of molecules and associated physico-chemical properties. The aim of this review is to give an outline of studies in the field of medicinal chemistry in which molecular modeling has helped in the discovery process of new drugs.
The traditional way of drug discovery is the experimental screening of large collections of chemicals against a biological target (high-throughput screening or HTS) for identifying new lead compounds. The application of rational, structure-based drug design is proven to be more capable than the traditional way of drug discovery since it aims to understand the molecular basis of a disease and utilizes the knowledge of the three-dimensional (3D) structure of the biological target in the process. State of the art structure-based drug design methods include virtual screening and de novo drug design; these serve as an efficient, alternative approach to HTS.
- Track 3-1Molecular Modelling: Principles and Applications
- Track 3-2Molecular graphics
- Track 3-3Monte Carlo method and Molecular design software
- Track 3-4Drug development
- Track 3-5Retrometabolic drug design
Technological advancements in the molecular characterization of cancers have assisted researchers to identify an increasing number of key molecular drivers of cancer progression. These discoveries have led to multiple novel anticancer therapeutics, and clinical advantage in selected patient populations. Despite this, the identification of clinically relevant predictive biomarkers of response continues to lag behind. In this review, we discuss strategies for the molecular characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics. The discovery and evaluation of any novel biomarkers will ideally be specialised to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers, and are crucial to accelerating the drug development process.
- Track 4-1Protein biomarkers in drug designing
- Track 4-2Clinical biomarkers in drug designing
- Track 4-3Biomarkers in drug discovery and development
- Track 4-4Applications of Imaging Biomarkers
It is driven by chemistry but gradually directed by pharmacology and the clinical Sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and instruction is important in fulfilling the public health. The initiation of molecular biology and, in particular, of genomic sciences is having a deep conclusion on drug discovery. Emphasis is positioned on the contrast between the academic and industrial research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that research directors aspect are also emphasized. In discovery process comprises the early phases of research, which are designed to identify an investigational drug and achieve primary tests in the lab. This first stage of the process proceeds almost three to six years. By the end, investigators hope to identify a accomplished drug aspirant to further study in the lab and in animal models, and then in people. These advances offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced.
- Track 5-1Flexible ligand docking
- Track 5-2Pharmacogenetics in Drug Discovery and Development
- Track 5-3Advancing Drug Discovery
- Track 5-4Pharmaceutical Industry Perspective
- Track 5-5Historical Perspective
- Track 5-6Accelerated Drug Discovery Perspectives
Drug Formulation is the study of relationships between pre formulation, pharmaceutical formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its preferred form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was restricted only for assessing few characteristics, but today this process is being considered as a formulation strategy and hence tremendous technological advancement has been accomplished in this field which enables us to save time and money through planned management system and hence impacts Drug Formulation 2017 to be a formulation conference. Use of glorious statistical software even based on artificial neural networking are made the task of pre formulation and optimization process easier. Role of pre formulation studies techniques like freeze drying aspects projects the event Drug Formulation 2017 to pose as a freeze drying meeting in drug discovery, drug development plays major role in pharmaceutical formulation development and the revisions will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of formulations unique to each drug. NDDS conference will discuss on Premature Approaches, Present Scenario and Future Prospects of Pre formulation events. There are more than 1400 sustained or controlled release drugs have been approved all over the world. Pharmaceutical conferences discuss the state-of-art technology being applied and involve advances in formulation studies.
Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
- Track 6-1Freeze Drying
- Track 6-2Hot Melt Extrusion
- Track 6-3Preformulation in Drug Development
- Track 6-4Preformulation in Drug Discovery
- Track 6-5Drug Formulation Considerations
- Track 6-6Major Challenges in Drug Development
- Track 6-7Physiological Drug Environment
Formulations are classified into two types: based on Route of administration and Physical form. Based on route of administration they are classified as Oral, Topica, Rectal, Parenteral, Vaginal, Inhaled, Ophthalmic and octic . A route of administration is the path by which a drug, fluid, poison, or other substance is involved into the body Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be categorised based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
- Track 7-1Inhalation formulations
- Track 7-2Development of oral dosage form
- Track 7-3Other routes
- Track 7-4Parenteral,Topical, Enternal
- Track 7-5Routes of administration: Oral, Rectal,Vaginal, Lingual etc
- Track 7-6Advantages and disadvantages
The drug subjected to drug development undergo number of trials and are screened at different stages to produce a final potent drug for the treatment of various diseases. During this process different properties are checked to see whether the drug is non-toxic to living system and is therapeutic or not. Using suitable excipients and technological preparations the active substances are formulated into final dosage form. The final product is the Actual composition of preparation, manufacturing specification.
A detailed analysis of the industry structure of contract manufacturing, contract research and contract packaging has been conducted. Revenues are broken down by type of industry. Sales figures are estimated for the five-year period from 2013 through 2018. The United States is currently spending almost $250 billion a year for prescription drugs. If drugs were sold in a competitive market, without government-imposed patent monopolies, this might achieve savings up to $200 billion a year.
- Track 8-1Advanced formulation techniques
- Track 8-2Types of coating and coating procedures
- Track 8-3Sterile filtration, Aseptic filling
- Track 8-4Lyophilized dosage forms
- Track 8-5Development of parenteral dosage form
- Track 8-6Validation process
Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.
Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of achievement is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall
- Track 9-1Excretion of Drugs
- Track 9-2Pharmacodynamics
- Track 9-3Pharmacokinetic Parameters
- Track 9-4Pharmacodynamic Parameters
- Track 9-5Absorption of Drugs
- Track 9-6Distribution of Drugs
- Track 9-7Biotransformation/Metabolism
Clinical Biotherapeutic aspects including study design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.
- Track 10-1Toxicology of therapeutic proteins
- Track 10-2Clinical development of therapeutic proteins
- Track 10-3Cancer Biotherapeutics
- Track 10-4Advancements in Biotherapeutics
- Track 10-5Preclinical Studies
- Track 10-6Identification of biomarkers at Preclinical stages
- Track 10-7Phase I Clinical development
- Track 10-8Phase II Clinical development
- Track 10-9Phase III Clinical development
Size reduction is a fundamental unit operation having important applications in pharmacy. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nano meter size range enhance performance in a variety of dosage forms. Major advantages of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.
Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative and highly specialized field, which will revolutionize the pharmaceutical industry in near future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against many diseases. It helps in detecting the antigen associated with diseases such as cancer, diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and viruses associated with infections. It is expected that in next 10 years market will be flooded with nanotechnology devised medicine.
- Track 11-1Pharmaceutical Nanotechnology based Systems
- Track 11-2Characterization of Pharmaceutical Nanotools
- Track 11-3Engineering of Pharmaceutical Nanosystems
- Track 11-4Applications of Pharmaceutical Nanotools
- Track 11-5Challenges to Pharmaceutical Nanotechnology
- Track 11-6Future Prospects of Pharmaceutical Nanotechnology
“Novel Drug delivery System (NDDS) refers to the formulations, systems and technologies for transporting a pharmaceutical compound in the body as it is needed to safely achieve its desired therapeutic effects. Drug delivery systems (DDS), are based on approaches that are interdisciplinary and that combine pharmaceutics, bio conjugate chemistry, and molecular biology. drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of provision is largely initiated on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is exclusively diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a susceptible drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted dispute system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more constant effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.
- Track 12-1Metal Nanoparticles and Quantum Dots
- Track 12-2Nanogels
- Track 12-3Cyclodextrins
- Track 12-4Micelles
- Track 12-5Dendrimers
- Track 12-6Organic Nanotubes: Promising Vehicles for Drug Delivery
- Track 12-7Liposomal Drug Delivery Systems
- Track 12-8Solid Lipid Nano and Microparticles
- Track 12-9Microemulsions and Nanoemulsions
- Track 12-10Polymers
Identifying drug targets plays essential roles in designing new drugs and combating diseases. Unfortunately, our current understanding about drug targets is far from comprehensive. Screening drug targets in the lab is an expensive and time-consuming procedure. In the past decade, the accumulation of various types of study of science related data makes it possible to develop computational approaches to predict drug targets. Non-communicable diseases such as cancer, atherosclerosis and diabetes are responsible for most important social and health affliction as millions of people are dying every year. Out of which, atherosclerosis is the leading cause of deaths worldwide. The lipid abnormality is one of the most important modifiable risk factors for atherosclerosis. Both genetic and environmental components are associated with the development of atherosclerotic plaques. Immune and inflammatory mediators have a complex role in the initiation and progression of atherosclerosis. Understanding of all these processes will help to invent a range of new biomarkers and novel treatment modalities targeting various cellular events in acute and chronic inflammation that are accountable for atherosclerosis. Several biochemical pathways, receptors and enzymes are involved in the development of atherosclerosis that would be possible targets for improving strategies for disease diagnosis and management.
- Track 13-1Novel Drug Target Approach for diabetes
- Track 13-2Novel Drug Target Approach for HIV
- Track 13-3Novel Drug Target Approach for cancer
- Track 13-4Novel Drug Target Approach for tuberculosis
- Track 13-5Novel Drug Target Approach for atherosclerosis
- Track 13-6Novel Drug Target Approach for dementia
Drug manufacturing (Pharmaceutical Manufacturing) is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be demolished down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others. The changing pharmaceutical landscape is a popular discussion point as of late. Armed with a fresh, non-blockbuster-reliant business model and treatment options that are expanding from small molecules to a range of new, more targeted therapies, the industry is at what PwC calls, “a critical juncture.”
Parenteral drug delivery is the second largest segment of this transformative pharmaceutical market covered only by the more mature oral solid dosage forms accounting for nearly 30 percent of total pharma market share. According to Survey, the market for parenteral drug delivery products is projected to rise over 10 percent annually to $86.5 billion in 2019.
- Track 14-1Process Development Tools
- Track 14-2Sterile filtration, Aseptic filling
- Track 14-3Lyophilisation
- Track 14-4Capping, Sealing & Labelling
Pharmaceutical engineering is a branch of pharmaceutical science and technology that involves development and manufacturing of products, processes, and components in the pharmaceuticals industry (i.e. drugs & biologics). While developing pharmaceutical products involves many interrelated disciplines (e.g. medicinal chemists, analytical chemists, clinicians/pharmacologists, pharmacists, chemical engineers, biomedical engineers, etc.), the specific subfield of "pharmaceutical engineering" has only emerged recently as a divergent engineering discipline. This now brings the problem-solving principles and quantitative training of engineering to complement the other scientific fields already involved in drug development.
- Track 15-1Equipment Design and Process Optimization
- Track 15-2Advanced Pharmaceutical Operations
- Track 15-3Pharmaceutical Dosage Form Technology
- Track 15-4Bioreactors
- Track 15-5Fluid Mechanics
- Track 15-6Design of process equipment
- Track 15-7Materials and Operations Management
As developers and manufacturers of life-saving products, the world’s leading pharmaceutical companies play an important eccentric in improving access to medicine for the world’s poor. Through their own initiatives and in collaboration with other relevant stakeholders such as multi-lateral organizations, governments and the global health community, these companies are increasingly helping to address the admittance to medicine challenge. In order to suitably capture the industry’s progress in line with society’s evolving expectations, the Access to Medicine Index methodology is systematically reviewed every two years. While maintaining as much consistency as possible for the purpose of trend analysis, the methodology is adjusted where needed.
- Track 16-1Modern Analytical Methodology
- Track 16-2Technological Innovations
- Track 16-3Microencapsulation
- Track 16-4Synthesis of heterocyclic compounds
- Track 16-5Chiral Separations
- Track 16-6HPLC technology
Regulatory Affairs conjointly includes a terribly specific which means among the attention industries pharmaceuticals, biologics, medical devices, and food industry. In recent years the growing quality of attention Regulatory Affairs has created nice challenges to satisfy the strain of native health authorities and regulatory agencies. Merely keeping up on changes within the needs for international and native markets will need a frenzied team of specialists.
The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.
- Track 17-1Compilation and maintenance of marketing Authorisation Applications
- Track 17-2SOPs and Policy Documents
- Track 17-3Quality Control
- Track 17-4Objective assessment
- Track 17-5Data Integrity towards Regulatory Affairs
For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start or expand their business.
If you’re thinking about a business opportunity that will require investment, then attend networking events in your area to identify key members of the investor community and meet other entrepreneurs. It is never too early to approach potential investors and it may be easier to create an informal relationship when you’re not actively seeking investment for your start-up.
- Track 18-1Social media strategy
- Track 18-2Do-a thorough financial analysis